Ketamine for the Treatment of Refractory Status Epilepticus
ConditionRefractory Status Epilepticus
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorThomas Jefferson University
About this trial
This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
Eligibility criteria
Qualifiers
Adults 18 years of age or older
Patients with refractory status epilepticus unresponsive to appropriately dosed first line agents administered intravenous or intraosseous and one second line agent
First line agents: lorazepam, midazolam, or diazepam
Second line agents: phenytoin (20 mg/kg), valproate (40 mg/kg), levetiracetam (60 mg/kg), lacosamide (400 mg)
Disqualifiers
Exclusively psychogenic non epileptic seizures
Pregnant individuals
Incarcerated individuals
Patients with hypersensitivity to ketamine or any component of the formulation
Trial design
Treatments tested in this trial
- Ketamine
- Midazolam
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov